Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer.

Eur Urol Open Sci · 2025 · PMC12167777 · PMID 40524688

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

did not reach statistical significancep = 0.2not close (p > 0.1)

Although the difference did not reach statistical significance, median PSA at mHSPC was lower in the PSA-N ≤0.02 group (2 vs 7 ng/ml for PSA-N 0.02–0.20 vs 23 ng/ml for PSA-N >0.02 ; p = 0.2).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.